Table 3. Treatment options and radiotherapy dose in relation to stage and primary tumour site.

n	Primary site	St I	St II	St III	St IV	St X	n × radiation dose (Gy)/n of fractions (reason of protocol violation)
Definitive IMRT (48 patients)
6	Oral cavity	1	3	2			6 × 70/35
15	Oropharynx	2	6	3	4		1 × 44/22 (toxic megacolon), 4 × 66/30, 2 × 66/33 (T1N0), 8 × 70/35
12	Nasopharynx	1		1	10		1 × 62/31 (patient refusal), 1 × 66/33 (T1N0), 2 × 68/34, 8 × 70/35
3	Hypopharynx				3		1 × 66/30, 2 × 70/35
6	Larynx	1	4		1		1 × 50/25 (prior supraclavicular RT), 3 × 66/33, 2 × 70/35
4	Sinus			1	3		1 × 50/25 (pre-operative), 1 × 60/30, 2 × 70/35
2	1 nose, 1 CUP				1	1	2 × 70/35
Post-operative IMRT (30 patients)
13	Oral cavity	2	3	3	5		2 × 60/30, 11 × 66/33
6	Oropharynx		2	2	2		1 × 60/30, 1 × 66/33, 1 × 68/34 (pos SM), 3 × 70/35 (pos SM)
1	Nasopharynx				1		1 × 70/35 (after adenoidectomy)
1	Larynx				1		1 × 56/28 (prior RT for lymphoma)
1	Sinus			3			3 × 66/33
6	Salivary gland	2	2	2			1 × 18/9 (intercurrent death), 3 × 66/33, 1 × 68/34 (pos SM), 1 × 70/35 (pos SM)
2	1 CUP, 1 EAC			1	1		1 × 60/30, 1 × 66/33

St, stage; CUP, carcinoma of unknown primary; EAC, external auditory canal; IMRT, intensity-modulated radiotherapy; pos SM, positive resection margins; RT, radiotherapy.